Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin plus insulin in Japanese adults with type 1 diabetes and inadequate glycemic control
jRCT2080223107Phase 3
- Sponsor
- AstraZeneca
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dapagliflozin in diabetes mellitus type 1 (T1D) (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety of dapagliflozin in combination with insulin, Efficacy in glycemic control and 2 more.
02
Drugs
dapagliflozin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on jRCT2080223107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223107.